View ValuationAedifica/SA 将来の成長Future 基準チェック /06Aedifica/SAの収益は年間34.9%で減少すると予測されていますが、年間収益は年間0.7%で増加すると予測されています。EPS は年間 減少すると予測されています。自己資本利益率は 3 年後に6.9% 35.3%なると予測されています。主要情報-34.9%収益成長率-35.26%EPS成長率Health Care REITs 収益成長-11.7%収益成長率0.7%将来の株主資本利益率6.95%アナリストカバレッジGood最終更新日21 May 2026今後の成長に関する最新情報お知らせ • Oct 30+ 3 more updatesAedifica NV/SA Revises Earnings Guidance for the Year 2025Aedifica NV/SA revised earnings guidance for the year 2025. For the year, the company expected EPRA Earnings for 2025 are increased to approx. €5.10/share (previously €5.01/share), excluding the transaction costs related to the exchange offer.お知らせ • Feb 21+ 1 more updateAedifica NV/SA Provides Earnings Guidance for the Year 2025Aedifica NV/SA provided earnings guidance for the year 2025. For the year, the company expected EPRA Earnings for 2025 are estimated at €238 million, or €5.01 per share.お知らせ • Oct 30Aedifica NV/SA Increases Earnings Guidance for the Year 2024Aedifica NV/SA increased earnings guidance for the year 2024. For the year, the company Estimated EPRA Earnings per share for the full 2024 financial year are increased to at least €4.90/share (previously €4.85/share).お知らせ • Jul 31Aedifica NV/SA Provides Earnings Guidance for the Year 2024Aedifica NV/SA provided earnings guidance for the year 2024. For the year, the company EPRA Earnings for 2024 are estimated at €231 million (previously €223 million). EPRA Earnings per share are estimated €4.85/share (previously €4.70/share).お知らせ • Nov 01Aedifica NV/SA Revises Earnings Guidance for the Year 2023Aedifica NV/SA revised earnings guidance for the year 2023. Estimated EPRA Earnings per share for the full 2023 financial year are increased to at least €4.95/share (previously €4.85/share), including a €0.21/share one-off EPRA result following the obtention of the FBI regime for the Dutch subsidiaries.お知らせ • Aug 04Aedifica NV/SA Revises Earnings Guidance for the Year 2023Aedifica NV/SA revised earnings guidance for the year 2023. Estimated EPRA Earnings for the 2023 financial year slightly increased to €212 million (previously €209 million) and EPRA Earnings per share are estimated at €4.85/share (previously €4.78/share).すべての更新を表示Recent updatesReported Earnings • May 21First quarter 2026 earnings released: EPS: €7.68 (vs €1.32 in 1Q 2025)First quarter 2026 results: EPS: €7.68 (up from €1.32 in 1Q 2025). Revenue: €117.8m (up 23% from 1Q 2025). Net income: €432.3m (up €369.5m from 1Q 2025). Revenue is forecast to stay flat during the next 3 years compared to a 3.1% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Board Change • May 20High number of new directorsThere are 7 new directors who have joined the board in the last 3 years. Independent Director Xavier de Walque was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Mar 05Aedifica NV/SA, Annual General Meeting, May 12, 2026Aedifica NV/SA, Annual General Meeting, May 12, 2026.お知らせ • Feb 13Aedifica Nv/Sa Proposes DividendThe Aedifica NV/SA proposed dividend of €4.00 per share (gross), to be distributed in May 2026, is confirmed.お知らせ • Oct 30+ 3 more updatesAedifica NV/SA Revises Earnings Guidance for the Year 2025Aedifica NV/SA revised earnings guidance for the year 2025. For the year, the company expected EPRA Earnings for 2025 are increased to approx. €5.10/share (previously €5.01/share), excluding the transaction costs related to the exchange offer.お知らせ • Oct 14Aedifica NV/SA to Report Fiscal Year 2025 Results on Feb 13, 2026Aedifica NV/SA announced that they will report fiscal year 2025 results at 7:30 AM, Central European Standard Time on Feb 13, 2026お知らせ • Feb 27Aedifica NV/SA to Report Nine Months, 2025 Results on Oct 28, 2025Aedifica NV/SA announced that they will report nine months, 2025 results on Oct 28, 2025お知らせ • Feb 21+ 1 more updateAedifica NV/SA Provides Earnings Guidance for the Year 2025Aedifica NV/SA provided earnings guidance for the year 2025. For the year, the company expected EPRA Earnings for 2025 are estimated at €238 million, or €5.01 per share.お知らせ • Nov 22Aedifica NV/SA to Report Q1, 2025 Results on Apr 29, 2025Aedifica NV/SA announced that they will report Q1, 2025 results at 5:40 PM, Central European Standard Time on Apr 29, 2025お知らせ • Oct 30Aedifica NV/SA Increases Earnings Guidance for the Year 2024Aedifica NV/SA increased earnings guidance for the year 2024. For the year, the company Estimated EPRA Earnings per share for the full 2024 financial year are increased to at least €4.90/share (previously €4.85/share).お知らせ • Oct 23Aedifica NV/SA to Report Fiscal Year 2024 Results on Feb 19, 2025Aedifica NV/SA announced that they will report fiscal year 2024 results at 7:30 AM, Central European Standard Time on Feb 19, 2025お知らせ • Sep 10Aedifica NV/SA (ENXTBR:AED) acquired Furze Field Manor, Copperfield Court & Rownhams Manor Trading Care Homes in UK of Oyster Care Homes Limited.Aedifica NV/SA (ENXTBR:AED) acquired Furze Field Manor, Copperfield Court & Rownhams Manor Trading Care Homes in UK of Oyster Care Homes Limited on September 6, 2024. In a separate transaction, Aedifica NV/SA signed an agreement to acquire Somer Valley House in Midsomer Norton from Oyster Care Homes Limited. The transactions had a combined deal value of £61.5 million. Aedifica NV/SA (ENXTBR:AED) completed the acquisition of Furze Field Manor, Copperfield Court & Rownhams Manor Trading Care Homes in UK of Oyster Care Homes Limited on September 6, 2024.お知らせ • Jul 31Aedifica NV/SA Provides Earnings Guidance for the Year 2024Aedifica NV/SA provided earnings guidance for the year 2024. For the year, the company EPRA Earnings for 2024 are estimated at €231 million (previously €223 million). EPRA Earnings per share are estimated €4.85/share (previously €4.70/share).お知らせ • May 03+ 2 more updatesAedifica NV/SA, Annual General Meeting, May 13, 2025Aedifica NV/SA, Annual General Meeting, May 13, 2025.Reported Earnings • Apr 06Full year 2023 earnings released: EPS: €0.56 (vs €8.71 in FY 2022)Full year 2023 results: EPS: €0.56 (down from €8.71 in FY 2022). Revenue: €321.1m (up 15% from FY 2022). Net income: €24.5m (down 93% from FY 2022). Profit margin: 7.6% (down from 119% in FY 2022). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 17% per year.Declared Dividend • Apr 04Final dividend of €1.60 announcedShareholders will receive a dividend of €1.60. Ex-date: 16th May 2024 Payment date: 22nd May 2024 Dividend yield will be 5.7%, which is lower than the industry average of 7.4%.Declared Dividend • Mar 01Final dividend of €1.60 announcedShareholders will receive a dividend of €1.60. Ex-date: 16th May 2024 Payment date: 22nd May 2024 Dividend yield will be 6.1%, which is lower than the industry average of 7.4%.お知らせ • Nov 01Aedifica NV/SA to Report Nine Months, 2024 Results on Oct 30, 2024Aedifica NV/SA announced that they will report nine months, 2024 results on Oct 30, 2024Reported Earnings • Nov 01Third quarter 2023 earnings released: EPS: €0.69 (vs €3.49 in 3Q 2022)Third quarter 2023 results: EPS: €0.69 (down from €3.49 in 3Q 2022). Revenue: €81.4m (up 15% from 3Q 2022). Net income: €32.8m (down 76% from 3Q 2022). Profit margin: 40% (down from 196% in 3Q 2022). Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings.お知らせ • Nov 01Aedifica NV/SA Revises Earnings Guidance for the Year 2023Aedifica NV/SA revised earnings guidance for the year 2023. Estimated EPRA Earnings per share for the full 2023 financial year are increased to at least €4.95/share (previously €4.85/share), including a €0.21/share one-off EPRA result following the obtention of the FBI regime for the Dutch subsidiaries.お知らせ • Sep 26+ 3 more updatesAedifica NV/SA to Report Fiscal Year 2023 Results on Feb 21, 2024Aedifica NV/SA announced that they will report fiscal year 2023 results on Feb 21, 2024お知らせ • Aug 04Aedifica NV/SA Revises Earnings Guidance for the Year 2023Aedifica NV/SA revised earnings guidance for the year 2023. Estimated EPRA Earnings for the 2023 financial year slightly increased to €212 million (previously €209 million) and EPRA Earnings per share are estimated at €4.85/share (previously €4.78/share).Valuation Update With 7 Day Price Move • Jun 28Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €52.53, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 21x in the Health Care REITs industry globally. Total loss to shareholders of 37% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €69.21 per share.Buying Opportunity • Jun 22Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 21%. The fair value is estimated to be €73.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 26%. For the next 3 years, revenue is forecast to grow by 7.5% per annum. Earnings is also forecast to grow by 22% per annum over the same time period.お知らせ • Jun 02An unknown buyer entered into an agreement to acquire portfolio of 10 buildings in Finland from Aedifica NV/SA (ENXTBR:AED) for €25.6 million.An unknown buyer entered into an agreement to acquire portfolio of 10 buildings in Finland from Aedifica NV/SA (ENXTBR:AED) for €25.6 million on June 1, 2023.The transaction is expected to be completed by the end of June 2023.Reported Earnings • May 11First quarter 2023 earnings released: EPS: €0.40 (vs €3.23 in 1Q 2022)First quarter 2023 results: EPS: €0.40 (down from €3.23 in 1Q 2022). Revenue: €78.6m (up 17% from 1Q 2022). Net income: €16.1m (down 86% from 1Q 2022). Profit margin: 21% (down from 174% in 1Q 2022). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Upcoming Dividend • May 06Upcoming dividend of €1.60 per share at 4.9% yieldEligible shareholders must have bought the stock before 12 May 2023. Payment date: 16 May 2023. Trailing yield: 4.9%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (6.5%).Reported Earnings • Apr 10Full year 2022 earnings released: EPS: €8.71 (vs €8.10 in FY 2021)Full year 2022 results: EPS: €8.71 (up from €8.10 in FY 2021). Revenue: €279.2m (up 15% from FY 2021). Net income: €331.8m (up 18% from FY 2021). Net asset value (NAV) per share: €82.37 (up 12% from FY 2021). The current share price is 13% lower than NAV per share. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 18Full year 2022 earnings released: EPS: €8.71 (vs €8.10 in FY 2021)Full year 2022 results: EPS: €8.71 (up from €8.10 in FY 2021). Revenue: €279.2m (up 15% from FY 2021). Net income: €331.8m (up 18% from FY 2021). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.お知らせ • Feb 16+ 1 more updateAedifica SA Proposes Earnings Guidance for the Year 2023Aedifica SA proposed earnings guidance for the year 2023. EPRA Earnings for 2023 are estimated at €200 million, or €5.03/share.Board Change • Nov 16High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Nov 09+ 2 more updatesAedifica SA to Report Q1, 2023 Results on May 10, 2023Aedifica SA announced that they will report Q1, 2023 results on May 10, 2023Board Change • Oct 20High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 01+ 1 more updateAedifica SA to Report Fiscal Year 2022 Final Results on Mar 30, 2023Aedifica SA announced that they will report fiscal year 2022 final results on Mar 30, 2023Board Change • Sep 08High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Aug 19High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 06Second quarter 2022 earnings released: EPS: €3.34 (vs €2.03 in 2Q 2021)Second quarter 2022 results: EPS: €3.34 (up from €2.03 in 2Q 2021). Revenue: €67.3m (up 17% from 2Q 2021). Net income: €121.9m (up 79% from 2Q 2021). Over the next year, revenue is forecast to grow 11%, compared to a 6.5% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Board Change • Jul 22High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Jun 30High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Jun 02High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • May 18High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Henrike Waldburg was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Upcoming Dividend • May 06Upcoming dividend of €1.58 per shareEligible shareholders must have bought the stock before 13 May 2022. Payment date: 17 May 2022. Trailing yield: 3.4%. Lower than top quartile of British dividend payers (4.7%). In line with average of industry peers (3.1%).Reported Earnings • Apr 03Full year 2021 earnings released: EPS: €8.10 (vs €4.35 in FY 2020)Full year 2021 results: EPS: €8.10 (up from €4.35 in FY 2020). Revenue: €242.7m (up 36% from FY 2020). Net income: €281.8m (up 144% from FY 2020). Over the next year, revenue is forecast to grow 14% while the reits industry in the United Kingdom is not expected to grow. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 9% per year.Buying Opportunity • Mar 05Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be €128, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% per annum over the last 3 years. Earnings per share has grown by 8.4% per annum over the last 3 years.Reported Earnings • Nov 13Third quarter 2021 earnings released: EPS €1.61 (vs €0.70 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €59.1m (up 26% from 3Q 2020). Net income: €58.2m (up 226% from 3Q 2020). Profit margin: 98% (up from 38% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Aug 12Second quarter 2021 earnings released: EPS €2.04 (vs €0.70 in 2Q 2020)Second quarter 2021 results: Revenue: €54.9m (up 17% from 2Q 2020). Net income: €68.1m (up 282% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • May 13First quarter 2021 earnings released: EPS €1.35 (vs €0.70 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €54.4m (up 16% from 1Q 2020). Net income: €44.7m (up 151% from 1Q 2020). Profit margin: 82% (up from 38% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 10% per year.Upcoming Dividend • May 07Upcoming dividend of €0.48 per shareEligible shareholders must have bought the stock before 14 May 2021. Payment date: 18 May 2021. Trailing yield: 3.0%. Lower than top quartile of British dividend payers (4.1%). In line with average of industry peers (3.0%).Is New 90 Day High Low • Feb 20New 90-day high: €104The company is up 5.0% from its price of €98.90 on 20 November 2020. The British market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the REITs industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €96.96 per share.Is New 90 Day High Low • Jan 28New 90-day high: €101The company is up 16% from its price of €86.50 on 30 October 2020. The British market is up 18% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the REITs industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €101 per share.業績と収益の成長予測BATS-CHIXE:AEDB - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028406262N/AN/A212/31/2027388269N/AN/A712/31/2026371246N/AN/A23/31/2026391614N/AN/AN/A12/31/2025369244318318N/A9/30/2025367228N/AN/AN/A6/30/2025361176291292N/A3/31/2025358192N/AN/AN/A12/31/2024347205248248N/A9/30/2024341106N/AN/AN/A6/30/2024334110233234N/A3/31/202432784N/AN/AN/A12/31/202332125229230N/A9/30/202331243N/AN/AN/A6/30/2023301150245246N/A3/31/2023290231N/AN/AN/A12/31/2022279332218219N/A9/30/2022273489N/AN/AN/A6/30/2022265408171171N/A3/31/2022254354N/AN/AN/A12/31/2021243282198198N/A9/30/2021216221N/AN/AN/A6/30/2021198193N/AN/AN/A3/31/2021188150N/AN/AN/A12/31/2020179115119121N/A6/30/2020169105111112N/A3/31/2020157129104106N/A12/31/2019146154N/A99N/A9/30/2019134139N/A94N/A6/30/2019122123N/A89N/A3/31/201911199N/A82N/A12/31/201810074N/A74N/A9/30/20189773N/A80N/A6/30/20189472N/A85N/A3/31/20189272N/A82N/A12/31/20178973N/A79N/A9/30/20178568N/A74N/A6/30/20178263N/A69N/A3/31/20177654N/A63N/A12/31/20167144N/A56N/A9/30/20166642N/A53N/A6/30/20166240N/A50N/A3/31/20166044N/A47N/A12/31/20155847N/A43N/A9/30/20155546N/A40N/A6/30/20155245N/A37N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: AEDBの収益は今後 3 年間で減少すると予測されています (年間-34.9% )。収益対市場: AEDBの収益は今後 3 年間で減少すると予測されています (年間-34.9% )。高成長収益: AEDBの収益は今後 3 年間で減少すると予測されています。収益対市場: AEDBの収益 ( 0.7% ) UK市場 ( 4.5% ) よりも低い成長が予測されています。高い収益成長: AEDBの収益 ( 0.7% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: AEDBの 自己資本利益率 は、3年後には低くなると予測されています ( 6.9 %)。成長企業の発掘7D1Y7D1Y7D1YReal-estate 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 10:26終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aedifica NV/SA 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。21 アナリスト機関Celine HuynhBarclaysCeline HuynhBarclaysKai KloseBerenberg18 その他のアナリストを表示
お知らせ • Oct 30+ 3 more updatesAedifica NV/SA Revises Earnings Guidance for the Year 2025Aedifica NV/SA revised earnings guidance for the year 2025. For the year, the company expected EPRA Earnings for 2025 are increased to approx. €5.10/share (previously €5.01/share), excluding the transaction costs related to the exchange offer.
お知らせ • Feb 21+ 1 more updateAedifica NV/SA Provides Earnings Guidance for the Year 2025Aedifica NV/SA provided earnings guidance for the year 2025. For the year, the company expected EPRA Earnings for 2025 are estimated at €238 million, or €5.01 per share.
お知らせ • Oct 30Aedifica NV/SA Increases Earnings Guidance for the Year 2024Aedifica NV/SA increased earnings guidance for the year 2024. For the year, the company Estimated EPRA Earnings per share for the full 2024 financial year are increased to at least €4.90/share (previously €4.85/share).
お知らせ • Jul 31Aedifica NV/SA Provides Earnings Guidance for the Year 2024Aedifica NV/SA provided earnings guidance for the year 2024. For the year, the company EPRA Earnings for 2024 are estimated at €231 million (previously €223 million). EPRA Earnings per share are estimated €4.85/share (previously €4.70/share).
お知らせ • Nov 01Aedifica NV/SA Revises Earnings Guidance for the Year 2023Aedifica NV/SA revised earnings guidance for the year 2023. Estimated EPRA Earnings per share for the full 2023 financial year are increased to at least €4.95/share (previously €4.85/share), including a €0.21/share one-off EPRA result following the obtention of the FBI regime for the Dutch subsidiaries.
お知らせ • Aug 04Aedifica NV/SA Revises Earnings Guidance for the Year 2023Aedifica NV/SA revised earnings guidance for the year 2023. Estimated EPRA Earnings for the 2023 financial year slightly increased to €212 million (previously €209 million) and EPRA Earnings per share are estimated at €4.85/share (previously €4.78/share).
Reported Earnings • May 21First quarter 2026 earnings released: EPS: €7.68 (vs €1.32 in 1Q 2025)First quarter 2026 results: EPS: €7.68 (up from €1.32 in 1Q 2025). Revenue: €117.8m (up 23% from 1Q 2025). Net income: €432.3m (up €369.5m from 1Q 2025). Revenue is forecast to stay flat during the next 3 years compared to a 3.1% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Board Change • May 20High number of new directorsThere are 7 new directors who have joined the board in the last 3 years. Independent Director Xavier de Walque was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 05Aedifica NV/SA, Annual General Meeting, May 12, 2026Aedifica NV/SA, Annual General Meeting, May 12, 2026.
お知らせ • Feb 13Aedifica Nv/Sa Proposes DividendThe Aedifica NV/SA proposed dividend of €4.00 per share (gross), to be distributed in May 2026, is confirmed.
お知らせ • Oct 30+ 3 more updatesAedifica NV/SA Revises Earnings Guidance for the Year 2025Aedifica NV/SA revised earnings guidance for the year 2025. For the year, the company expected EPRA Earnings for 2025 are increased to approx. €5.10/share (previously €5.01/share), excluding the transaction costs related to the exchange offer.
お知らせ • Oct 14Aedifica NV/SA to Report Fiscal Year 2025 Results on Feb 13, 2026Aedifica NV/SA announced that they will report fiscal year 2025 results at 7:30 AM, Central European Standard Time on Feb 13, 2026
お知らせ • Feb 27Aedifica NV/SA to Report Nine Months, 2025 Results on Oct 28, 2025Aedifica NV/SA announced that they will report nine months, 2025 results on Oct 28, 2025
お知らせ • Feb 21+ 1 more updateAedifica NV/SA Provides Earnings Guidance for the Year 2025Aedifica NV/SA provided earnings guidance for the year 2025. For the year, the company expected EPRA Earnings for 2025 are estimated at €238 million, or €5.01 per share.
お知らせ • Nov 22Aedifica NV/SA to Report Q1, 2025 Results on Apr 29, 2025Aedifica NV/SA announced that they will report Q1, 2025 results at 5:40 PM, Central European Standard Time on Apr 29, 2025
お知らせ • Oct 30Aedifica NV/SA Increases Earnings Guidance for the Year 2024Aedifica NV/SA increased earnings guidance for the year 2024. For the year, the company Estimated EPRA Earnings per share for the full 2024 financial year are increased to at least €4.90/share (previously €4.85/share).
お知らせ • Oct 23Aedifica NV/SA to Report Fiscal Year 2024 Results on Feb 19, 2025Aedifica NV/SA announced that they will report fiscal year 2024 results at 7:30 AM, Central European Standard Time on Feb 19, 2025
お知らせ • Sep 10Aedifica NV/SA (ENXTBR:AED) acquired Furze Field Manor, Copperfield Court & Rownhams Manor Trading Care Homes in UK of Oyster Care Homes Limited.Aedifica NV/SA (ENXTBR:AED) acquired Furze Field Manor, Copperfield Court & Rownhams Manor Trading Care Homes in UK of Oyster Care Homes Limited on September 6, 2024. In a separate transaction, Aedifica NV/SA signed an agreement to acquire Somer Valley House in Midsomer Norton from Oyster Care Homes Limited. The transactions had a combined deal value of £61.5 million. Aedifica NV/SA (ENXTBR:AED) completed the acquisition of Furze Field Manor, Copperfield Court & Rownhams Manor Trading Care Homes in UK of Oyster Care Homes Limited on September 6, 2024.
お知らせ • Jul 31Aedifica NV/SA Provides Earnings Guidance for the Year 2024Aedifica NV/SA provided earnings guidance for the year 2024. For the year, the company EPRA Earnings for 2024 are estimated at €231 million (previously €223 million). EPRA Earnings per share are estimated €4.85/share (previously €4.70/share).
お知らせ • May 03+ 2 more updatesAedifica NV/SA, Annual General Meeting, May 13, 2025Aedifica NV/SA, Annual General Meeting, May 13, 2025.
Reported Earnings • Apr 06Full year 2023 earnings released: EPS: €0.56 (vs €8.71 in FY 2022)Full year 2023 results: EPS: €0.56 (down from €8.71 in FY 2022). Revenue: €321.1m (up 15% from FY 2022). Net income: €24.5m (down 93% from FY 2022). Profit margin: 7.6% (down from 119% in FY 2022). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 17% per year.
Declared Dividend • Apr 04Final dividend of €1.60 announcedShareholders will receive a dividend of €1.60. Ex-date: 16th May 2024 Payment date: 22nd May 2024 Dividend yield will be 5.7%, which is lower than the industry average of 7.4%.
Declared Dividend • Mar 01Final dividend of €1.60 announcedShareholders will receive a dividend of €1.60. Ex-date: 16th May 2024 Payment date: 22nd May 2024 Dividend yield will be 6.1%, which is lower than the industry average of 7.4%.
お知らせ • Nov 01Aedifica NV/SA to Report Nine Months, 2024 Results on Oct 30, 2024Aedifica NV/SA announced that they will report nine months, 2024 results on Oct 30, 2024
Reported Earnings • Nov 01Third quarter 2023 earnings released: EPS: €0.69 (vs €3.49 in 3Q 2022)Third quarter 2023 results: EPS: €0.69 (down from €3.49 in 3Q 2022). Revenue: €81.4m (up 15% from 3Q 2022). Net income: €32.8m (down 76% from 3Q 2022). Profit margin: 40% (down from 196% in 3Q 2022). Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings.
お知らせ • Nov 01Aedifica NV/SA Revises Earnings Guidance for the Year 2023Aedifica NV/SA revised earnings guidance for the year 2023. Estimated EPRA Earnings per share for the full 2023 financial year are increased to at least €4.95/share (previously €4.85/share), including a €0.21/share one-off EPRA result following the obtention of the FBI regime for the Dutch subsidiaries.
お知らせ • Sep 26+ 3 more updatesAedifica NV/SA to Report Fiscal Year 2023 Results on Feb 21, 2024Aedifica NV/SA announced that they will report fiscal year 2023 results on Feb 21, 2024
お知らせ • Aug 04Aedifica NV/SA Revises Earnings Guidance for the Year 2023Aedifica NV/SA revised earnings guidance for the year 2023. Estimated EPRA Earnings for the 2023 financial year slightly increased to €212 million (previously €209 million) and EPRA Earnings per share are estimated at €4.85/share (previously €4.78/share).
Valuation Update With 7 Day Price Move • Jun 28Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €52.53, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 21x in the Health Care REITs industry globally. Total loss to shareholders of 37% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €69.21 per share.
Buying Opportunity • Jun 22Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 21%. The fair value is estimated to be €73.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 26%. For the next 3 years, revenue is forecast to grow by 7.5% per annum. Earnings is also forecast to grow by 22% per annum over the same time period.
お知らせ • Jun 02An unknown buyer entered into an agreement to acquire portfolio of 10 buildings in Finland from Aedifica NV/SA (ENXTBR:AED) for €25.6 million.An unknown buyer entered into an agreement to acquire portfolio of 10 buildings in Finland from Aedifica NV/SA (ENXTBR:AED) for €25.6 million on June 1, 2023.The transaction is expected to be completed by the end of June 2023.
Reported Earnings • May 11First quarter 2023 earnings released: EPS: €0.40 (vs €3.23 in 1Q 2022)First quarter 2023 results: EPS: €0.40 (down from €3.23 in 1Q 2022). Revenue: €78.6m (up 17% from 1Q 2022). Net income: €16.1m (down 86% from 1Q 2022). Profit margin: 21% (down from 174% in 1Q 2022). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Upcoming Dividend • May 06Upcoming dividend of €1.60 per share at 4.9% yieldEligible shareholders must have bought the stock before 12 May 2023. Payment date: 16 May 2023. Trailing yield: 4.9%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (6.5%).
Reported Earnings • Apr 10Full year 2022 earnings released: EPS: €8.71 (vs €8.10 in FY 2021)Full year 2022 results: EPS: €8.71 (up from €8.10 in FY 2021). Revenue: €279.2m (up 15% from FY 2021). Net income: €331.8m (up 18% from FY 2021). Net asset value (NAV) per share: €82.37 (up 12% from FY 2021). The current share price is 13% lower than NAV per share. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 18Full year 2022 earnings released: EPS: €8.71 (vs €8.10 in FY 2021)Full year 2022 results: EPS: €8.71 (up from €8.10 in FY 2021). Revenue: €279.2m (up 15% from FY 2021). Net income: €331.8m (up 18% from FY 2021). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
お知らせ • Feb 16+ 1 more updateAedifica SA Proposes Earnings Guidance for the Year 2023Aedifica SA proposed earnings guidance for the year 2023. EPRA Earnings for 2023 are estimated at €200 million, or €5.03/share.
Board Change • Nov 16High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 09+ 2 more updatesAedifica SA to Report Q1, 2023 Results on May 10, 2023Aedifica SA announced that they will report Q1, 2023 results on May 10, 2023
Board Change • Oct 20High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 01+ 1 more updateAedifica SA to Report Fiscal Year 2022 Final Results on Mar 30, 2023Aedifica SA announced that they will report fiscal year 2022 final results on Mar 30, 2023
Board Change • Sep 08High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Aug 19High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 06Second quarter 2022 earnings released: EPS: €3.34 (vs €2.03 in 2Q 2021)Second quarter 2022 results: EPS: €3.34 (up from €2.03 in 2Q 2021). Revenue: €67.3m (up 17% from 2Q 2021). Net income: €121.9m (up 79% from 2Q 2021). Over the next year, revenue is forecast to grow 11%, compared to a 6.5% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Board Change • Jul 22High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jun 30High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jun 02High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • May 18High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Henrike Waldburg was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • May 06Upcoming dividend of €1.58 per shareEligible shareholders must have bought the stock before 13 May 2022. Payment date: 17 May 2022. Trailing yield: 3.4%. Lower than top quartile of British dividend payers (4.7%). In line with average of industry peers (3.1%).
Reported Earnings • Apr 03Full year 2021 earnings released: EPS: €8.10 (vs €4.35 in FY 2020)Full year 2021 results: EPS: €8.10 (up from €4.35 in FY 2020). Revenue: €242.7m (up 36% from FY 2020). Net income: €281.8m (up 144% from FY 2020). Over the next year, revenue is forecast to grow 14% while the reits industry in the United Kingdom is not expected to grow. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 9% per year.
Buying Opportunity • Mar 05Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be €128, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% per annum over the last 3 years. Earnings per share has grown by 8.4% per annum over the last 3 years.
Reported Earnings • Nov 13Third quarter 2021 earnings released: EPS €1.61 (vs €0.70 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €59.1m (up 26% from 3Q 2020). Net income: €58.2m (up 226% from 3Q 2020). Profit margin: 98% (up from 38% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Aug 12Second quarter 2021 earnings released: EPS €2.04 (vs €0.70 in 2Q 2020)Second quarter 2021 results: Revenue: €54.9m (up 17% from 2Q 2020). Net income: €68.1m (up 282% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • May 13First quarter 2021 earnings released: EPS €1.35 (vs €0.70 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €54.4m (up 16% from 1Q 2020). Net income: €44.7m (up 151% from 1Q 2020). Profit margin: 82% (up from 38% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 10% per year.
Upcoming Dividend • May 07Upcoming dividend of €0.48 per shareEligible shareholders must have bought the stock before 14 May 2021. Payment date: 18 May 2021. Trailing yield: 3.0%. Lower than top quartile of British dividend payers (4.1%). In line with average of industry peers (3.0%).
Is New 90 Day High Low • Feb 20New 90-day high: €104The company is up 5.0% from its price of €98.90 on 20 November 2020. The British market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the REITs industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €96.96 per share.
Is New 90 Day High Low • Jan 28New 90-day high: €101The company is up 16% from its price of €86.50 on 30 October 2020. The British market is up 18% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the REITs industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €101 per share.